高血压药物相关基因位点多态性分布现况
Distribution of Polymorphisms of Drug-Related Gene Loci in Hypertension
摘要: 高血压是心脑血管病的首要危险因素。服用降压药物是目前控制高血压的最主要的措施，然而个体间药物疗效差异性大。药物基因组学发现个体间相关基因位点分布存在多态性。现阶段在多个地区已开展降压药物相关代谢基因位点多态性检测并指导临床用药，其疗效优于传统经验用药。因此，本文旨在对该领域的相关进展进行综述，为高血压药物治疗提供依据。
Abstract: Hypertension is the primary risk factor for cardiovascular and cerebrovascular diseases. At present, taking antihypertensive drugs is the most important measure to control hypertension, but the drug effect varies greatly among individuals. Pharmacogenomics found polymorphism in the distribution of relevant loci among individuals. At present, polymorphism detection of metabolic gene loci re-lated to antihypertensive drugs has been carried out in many areas to guide clinical drug use, and its efficacy is better than traditional empirical drugs. Therefore, this article aims to review the rel-evant progress in this field and provide basis for the drug treatment of hypertension.
文章引用：汪晓媛. 高血压药物相关基因位点多态性分布现况[J]. 临床医学进展, 2023, 13(8): 13690-13695. https://doi.org/10.12677/ACM.2023.1381913

参考文献

[1] Hiltunen, T.P., Donner, K.M., Sarin, A.P., Saarela, J., Ripatti, S., Chapman, A.B., Gums, J.G., Gong, Y., Cooper-DeHoffff, R.M., Frau, F., et al. (2015) Pharmacogenomics of Hypertension: A Genome-Wide, Place-bo-Controlled Cross-Over Study, Using Four Classes of Antihypertensive Drugs. Journal of the American Heart Asso-ciation, 4, e001521. [Google Scholar] [CrossRef] 
[2] Padmanabhan, S., Newton-Cheh, C. and Dominiczak, A. (2012) Genetic Basis of Blood Pressure and Hypertension. Trends in Genetics, 28, 397-408. [Google Scholar] [CrossRef] [PubMed]
[3] Ehret, G.B. and Caulfield, M.J. (2013) Genes for Blood Pressure: An Opportunity to Understand Hypertension. European Heart Journal, 34, 951-961. [Google Scholar] [CrossRef] [PubMed]
[4] Munroe, P.B., Barnes, M.R. and Caulfield, M.J. (2013) Advances in Blood Pressure Genomics. Circulation Research, 112, 1365-1379. [Google Scholar] [CrossRef] 
[5] 刘力生, 吴兆苏, 王文, 等. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治, 2019, 19(1): 6-49.
[6] Yasar, Ü., Forslund-Bergengren, C., Tybring, G., et al. (2002) Pharmacokinetics of Losartan and Its Metabolite E-3174 in Relation to the CYP2C9 Genotype. Clinical Pharma-cology & Therapeutics, 71, 89-98. [Google Scholar] [CrossRef] [PubMed]
[7] Yasar, Ü., Tybring, G., Hidestrand, M., et al. (2001) Role of CYP2C9 Polymorphism in Losartan Oxidation. Drug Metabolism and Disposition, 29, 1051-1056.
[8] Garimella, P.S., du Toit, C., Le, N.N. and Padmanabhan, S. (2023) A Genomic Deep Field View of Hypertension. Kidney International, 103, 42-52. [Google Scholar] [CrossRef] [PubMed]
[9] Lifton, R.P., Gharavi, A.G. and Geller, D.S. (2001) Molecular Mechanisms of Human Hypertension. Cell, 104, 545-556. [Google Scholar] [CrossRef] 
[10] Pazoki, R., Dehghan, A., Evangelou, E., et al. (2018) Genetic Predisposition to High Blood Pressure and Lifestyle Factors: Associations with Midlife Blood Pressure Levels and Car-diovascular Events. Circulation, 137, 653-661. [Google Scholar] [CrossRef] 
[11] Giri, A., Hellwege, J.N., Keaton, J.M., et al. (2019) Trans-Ethnic Association Study of Blood Pressure Determinants in over 750, 000 Individuals. Nature Genetics, 51, 51-62. [Google Scholar] [CrossRef] [PubMed]
[12] Surendran, P., Feofanova, E.V., Lahrouchi, N., et al. (2020) Discovery of Rare Variants Associated with Blood Pressure Regulation through Meta-Analysis of 1.3 Million Individu-als. Nature Genetics, 52, 1314-1332. [Google Scholar] [CrossRef] [PubMed]
[13] Sakaue, S., Kanai, M., Tanigawa, Y., et al. (2021) A Cross-Population Atlas of Genetic Associations for 220 Human Phenotypes. Nature Genetics, 53, 1415-1424. [Google Scholar] [CrossRef] [PubMed]
[14] Backman, J.D., Li, A.H., Marcketta, A., et al. (2021) Exome Sequencing and Analysis of 454,787 UK Biobank Participants. Nature, 599, 628-634. [Google Scholar] [CrossRef] [PubMed]
[15] Padmanabhan, S. and Dominiczak, A.F. (2021) Genomics of Hypertension: The Road to Precision Medicine. Nature Reviews Cardiology, 18, 235-250. [Google Scholar] [CrossRef] [PubMed]
[16] Torkamani, A., Wineinger, N.E. and Topol, E.J. (2018) The Personal and Clinical Utility of Polygenic Risk Scores. Nature Reviews Cardiology, 19, 581-590. [Google Scholar] [CrossRef] [PubMed]
[17] Loos, R.J. (2011) Genetics: Genome-Wide Risk Profiles—Will They Change Your Life (Style)? Nature Reviews Endocrinology, 7, 252-254. [Google Scholar] [CrossRef] [PubMed]
[18] Torrellas, C., Carril, J.C. and Cacabelos, R. (2014) Benefits of Phar-macogenetics in the Management of Hypertension. Journal of Pharmacogenomics & Pharmacoproteomics, 5, Article ID: 1000126. [Google Scholar] [CrossRef] 
[19] Cacabelos, R. (2012) The Metabolomic Paradigm of Phar-macogenomics in Complex Disorders. Metabolomics, 2, e119. [Google Scholar] [CrossRef] 
[20] Cooper-DeHoff, R.M. and Johnson, J.A. (2016) Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches. Nature Reviews Nephrology, 12, 110-122. [Google Scholar] [CrossRef] [PubMed]
[21] Ye, Y., Kuhn, C., Kösters, M., et al. (2019) Anti α-Enolase Antibody Is a Novel Autoimmune Biomarker for Unexplained Recurrent Miscarriages. EBioMedicine, 41, 610-622. [Google Scholar] [CrossRef] [PubMed]
[22] 冯星, 高超, 杨柏松, 康效嘉, 刘晓梅. 性别因素对吉林地区满族人抗高血压药物基因多态性的影响[J]. 中国地方病防治, 2020, 35(4): 480-482.
[23] 孙思雨, 尚茂林. 蚌埠地区高血压病人药物基因多态性的分布[J]. 蚌埠医学院学报, 2022, 47(7): 912-916. [Google Scholar] [CrossRef] 
[24] 王申, 张舜华, 薛薇, 王鹏飞, 任格, 陈传军. 沙坦类药物代谢酶CYP2C9的基因遗传多态性在高血压患者中的分布特征[J]. 中国循证心血管医学杂志, 2021, 13(6): 712-715.
[25] 易珍奎. 286例高血压患者的抗高血压药物相关基因多态性分析[J]. 中国处方药, 2022, 20(4): 47-48.
[26] 邓明影, 冯晓俊, 沈爱宗, 张蕾. 安徽地区高血压药物基因多态性分布与降压药个体化应用分析[J]. 中国医院药学杂志, 2022, 42(8): 827-831. [Google Scholar] [CrossRef] 
[27] 陈盈, 杨晓燕, 张金山, 陈连华, 石红. 降压药物相关基因多态性在肥城地区高血压人群中的分布研究[J]. 心血管病防治知识, 2021, 11(33): 20-24.
[28] 喻晶, 杨璐, 张舒琼, 王秋, 姜航. 7个高血压药物相关基因的多态性在582例汉族高血压患者中的分布[J]. 国际检验医学杂志, 2021, 42(3): 325-328+333.
[29] 高菊英, 刘丽宏, 万子睿, 李润堂, 田艳, 赵娜, 赵辉, 邓丽梅, 柴佳星, 王淑玲, 孙莉. 抗高血压药物基因多态性对呼伦贝尔地区三少民族高血压患者个体化治疗方案的参考价值[J]. 中国药物应用与监测, 2022, 19(3): 145-149.
[30] 李柳, 王亚茹, 张娣, 陈勤聪, 王明, 王硕. 高血压个体化用药基因检测在Ⅲ级高血压患者中的应用[J]. 昆明医科大学学报, 2022, 43(4): 112-117.
[31] 肖智林, 楚志文, 杨梅, 谢秀梅, 陈美芳. 药物基因组学导向高血压个体化用药的临床研究[J]. 中国实用内科杂志, 2020, 40(10): 850-854. [Google Scholar] [CrossRef] 
[32] Xiao, Z.-L., Yang, M., Chen, X.-B., Xie, X.-M. and Chen, M.-F. (2022) Personalized Antihypertensive Treatment Guided by Phar-macogenomics in China. Cardiovascular Diagnosis and Therapy, 12, 635-645. [Google Scholar] [CrossRef] [PubMed]
[33] 李晨瑜. 药物基因组学对唐山地区高血压人群降压疗效的影响[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2022.[CrossRef] 
[34] Beitelshees, A.L., Gong, Y., Wang, D., Schork, N.J., Cooper-Dehoff, R.M., Langaee, T.Y., Shriver, M.D., Sadee, W., Knot, H.J., Pepine, C.J., et al. (2007) KCNMB1 Geno-type Influences Response to Verapamil SR and Adverse Outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 17, 719-729. [Google Scholar] [CrossRef] 

为你推荐